QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NYSE:RDY

Dr. Reddy's Laboratories - RDY Stock Forecast, Price & News

$52.91
-0.26 (-0.49%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$52.78
▼
$53.29
50-Day Range
$51.38
▼
$57.32
52-Week Range
$47.88
▼
$67.76
Volume
130,758 shs
Average Volume
192,049 shs
Market Capitalization
$8.81 billion
P/E Ratio
22.61
Dividend Yield
0.60%
Price Target
$70.00

Dr. Reddy's Laboratories MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.3% Upside
$70.00 Price Target
Short Interest
Bearish
0.78% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
19.14%
From $2.56 to $3.05 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

176th out of 1,098 stocks

Pharmaceutical Preparations Industry

70th out of 536 stocks

See Top Rated MarketRank™ Stocks Here
RDY stock logo

About Dr. Reddy's Laboratories (NYSE:RDY) Stock

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Stock Down 0.5 %

Dr. Reddy's Laboratories stock traded down $0.26 during mid-day trading on Tuesday, reaching $52.91. The company's stock had a trading volume of 130,758 shares, compared to its average volume of 192,049. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of 22.61 and a beta of 0.46. Dr. Reddy's Laboratories has a 12 month low of $47.88 and a 12 month high of $67.76. The business's 50 day simple moving average is $54.70 and its 200 day simple moving average is $54.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.41 and a current ratio of 1.98.

Dr. Reddy's Laboratories (NYSE:RDY - Get Rating) last released its earnings results on Thursday, May 19th. The company reported $0.53 earnings per share for the quarter. The business had revenue of $717.00 million during the quarter. Dr. Reddy's Laboratories had a net margin of 13.63% and a return on equity of 18.61%. As a group, research analysts anticipate that Dr. Reddy's Laboratories will post 2.56 earnings per share for the current year.

Dr. Reddy's Laboratories Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Monday, July 11th. Stockholders of record on Monday, July 11th were given a $0.325 dividend. This represents a dividend yield of 0.58%. The ex-dividend date of this dividend was Friday, July 8th. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.29. Dr. Reddy's Laboratories's dividend payout ratio (DPR) is 13.68%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on RDY shares. Barclays increased their target price on shares of Dr. Reddy's Laboratories from $69.00 to $70.00 and gave the stock an "overweight" rating in a report on Tuesday, May 24th. StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, June 23rd. Finally, TheStreet lowered shares of Dr. Reddy's Laboratories from a "b" rating to a "c+" rating in a report on Friday, July 22nd.

Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

RDY Stock News Headlines

August 2, 2022 | nasdaq.com
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?
August 2, 2022 | americanbankingnews.com
Dr. Reddy's Laboratories Limited to Post FY2024 Earnings of $2.85 Per Share, Jefferies Financial Group Forecasts (NYSE:RDY)
July 31, 2022 | seekingalpha.com
Dr. Reddy's Laboratories Limited's (RDY) CEO Erez Israeli on Q1 2023 Results - Earnings Call Transcript
July 31, 2022 | seekingalpha.com
Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth
July 29, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
July 28, 2022 | americanbankingnews.com
Dr. Reddy's Laboratories (NYSE:RDY) Price Target Lowered to $68.00 at Barclays
July 27, 2022 | apnews.com
Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
July 27, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
July 22, 2022 | finance.yahoo.com
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
July 8, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
July 8, 2022 | msn.com
Dr Reddys Laboratories Q1 PAT seen up 15.9% YoY to Rs 661.8 cr: Prabhudas Lilladher
June 21, 2022 | morningstar.com
Dr Reddy's Laboratories Ltd ADR - Stock Dividends RDY
June 14, 2022 | seekingalpha.com
Dr. Reddy's launches generic version of Bayer's kidney/liver cancer drug Nexavar in US
May 27, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
May 24, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market
May 21, 2022 | apnews.com
Doctor Reddy’s: Fiscal Q4 Earnings Snapshot
May 11, 2022 | nasdaq.com
Oversold Conditions For Dr. Reddy's Laboratories (RDY)
April 20, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
April 5, 2022 | seekingalpha.com
Dr. Reddy’s launches methylprednisolone sodium succinate for injection in US
April 5, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market
April 1, 2022 | msn.com
Dr. Reddy's Laboratories & MediCane Health To Launch Medical Cannabis Products In Germany
April 1, 2022 | seekingalpha.com
Novartis agrees to sell heart disease drug, Cidmus to Dr. Reddy's in India
April 1, 2022 | finance.yahoo.com
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
February 21, 2022 | morningstar.com
Dr Reddy's Laboratories Ltd ADR RDY
February 15, 2022 | seekingalpha.com
Novartis to cut 400 jobs in India following distribution deal with Dr. Reddy's
See More Headlines
Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

RDY Company Calendar

Last Earnings
5/19/2022
Ex-Dividend for 7/11 Dividend
7/08/2022
Dividend Payable
7/11/2022
Today
8/09/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:RDY
CUSIP
N/A
CIK
1135951
Web
www.drreddys.com
Phone
914049002900
Fax
91-40-4900-2999
Employees
24,795
Year Founded
1984

Price Target and Rating

Average Stock Price Forecast
$70.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+32.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.34
Trailing P/E Ratio
22.61
Forward P/E Ratio
20.67
P/E Growth
N/A
Net Income
$311 million
Net Margins
13.63%
Pretax Margin
17.81%
Return on Equity
18.61%
Return on Assets
12.38%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.98
Quick Ratio
1.41

Sales & Book Value

Annual Sales
$2.83 billion
Price / Sales
3.12
Cash Flow
$3.30 per share
Price / Cash Flow
16.05
Book Value
$15.09 per share
Price / Book
3.51

Miscellaneous

Outstanding Shares
166,441,000
Free Float
163,112,000
Market Cap
$8.81 billion
Optionable
Optionable
Beta
0.46

Social Links


Key Executives

  • Mr. Gunupati Venkateswara Prasad B.E. (Age 62)
    Co-Chairman, MD & Member of Management Council
    Comp: $1.97M
  • Mr. Kallam Satish Reddy B.Tech. (Age 55)
    M.S., Chairman & Member of the Management Council
    Comp: $1.29M
  • Mr. Erez Israeli M.B.A. (Age 54)
    CEO & Member of the Management Council
  • Mr. Parag Agarwal (Age 56)
    CFO & Member of Management Council
  • Mr. Deepak Sapra M.B.A. (Age 47)
    CEO of API & Services & Member of Management Council
  • Mr. Venkata Ramana Motupalli M.B.A. (Age 53)
    MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council
  • Ms. Archana Bhaskar B.Sc. (Age 55)
    M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council
  • Mr. Sanjay Sharma B.Tech. (Age 54)
    Exec. VP, Global Head of Global Manufacturing & Member of Management Council
  • Mr. Marc Kikuchi B.A. (Age 53)
    M.B.A., CEO of North America Generics & Member of Management Council
  • Mr. Patrick Aghanian B.A. (Age 57)
    M.B.A., CEO of European Generics & Member of Management Council

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RDY Stock - Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RDY shares.
View RDY analyst ratings or view top-rated stocks.

What is Dr. Reddy's Laboratories' stock price forecast for 2022?

1 Wall Street analysts have issued twelve-month price objectives for Dr. Reddy's Laboratories' stock. Their RDY share price forecasts range from $70.00 to $70.00. On average, they predict the company's share price to reach $70.00 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price.
View analysts price targets for RDY or view top-rated stocks among Wall Street analysts.

How has Dr. Reddy's Laboratories' stock performed in 2022?

Dr. Reddy's Laboratories' stock was trading at $65.41 at the beginning of the year. Since then, RDY shares have decreased by 19.0% and is now trading at $52.95.
View the best growth stocks for 2022 here.

Are investors shorting Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,300,000 shares, a decrease of 26.6% from the June 15th total of 1,770,000 shares. Based on an average daily volume of 191,300 shares, the days-to-cover ratio is presently 6.8 days.
View Dr. Reddy's Laboratories' Short Interest.

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our RDY earnings forecast.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings data on Thursday, May, 19th. The company reported $0.53 earnings per share for the quarter. The business earned $717 million during the quarter. Dr. Reddy's Laboratories had a net margin of 13.63% and a trailing twelve-month return on equity of 18.61%.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories declared an annual dividend on Tuesday, May 24th. Investors of record on Monday, July 11th will be paid a dividend of $0.325 per share on Monday, July 11th. This represents a dividend yield of 0.58%. The ex-dividend date of this dividend is Friday, July 8th. This is a positive change from the stock's previous annual dividend of $0.29.
Read our dividend analysis for RDY.

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.62%. The dividend payout ratio is 13.68%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 10.49% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RDY.

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.08%), Connor Clark & Lunn Investment Management Ltd. (0.06%), US Bancorp DE (0.01%), Channing Global Advisors LLC (0.01%), Envestnet Asset Management Inc. (0.01%) and SG Americas Securities LLC (0.00%).

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $52.95.

How much money does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories (NYSE:RDY) has a market capitalization of $8.81 billion and generates $2.83 billion in revenue each year. The company earns $311 million in net income (profit) each year or $2.34 on an earnings per share basis.

How many employees does Dr. Reddy's Laboratories have?

Dr. Reddy's Laboratories employs 24,795 workers across the globe.

When was Dr. Reddy's Laboratories founded?

Dr. Reddy's Laboratories was founded in 1984.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The official website for the company is www.drreddys.com. The company can be reached via phone at 914049002900, via email at amita@drreddys.com, or via fax at 91-40-4900-2999.

This page (NYSE:RDY) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.